Major Program
Supportive Care and Symptom Management
Research Group
Community Oncology and Prevention Trials
Sponsor
University of Wisconsin, Madison
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02138214
This phase II trial studies how well thyroid gland removal with or without central lymph node dissection works in treating patients with thyroid cancer or suspected thyroid cancer that has not spread to the lymph nodes (randomized into Arms I and II). Arms I and II are compared to a standard of care (SOC) Arm III to enable comparison of quality of life among various surgical treatments. Currently, the standard treatment for thyroid cancer is total thyroidectomy, or complete removal of the thyroid. The lymph nodes in the central part of the neck may also be surgically removed, called central lymph node dissection. Prophylactic removal of the lymph nodes may increase the risk of life-threatening complications, and may reduce post-surgery quality of life. It may also prevent the cancer from returning and reduce the need for additional surgery. It is not yet known whether recurrence rates and complication levels are lower after thyroid gland removal alone or with central lymph node dissection.
Intervention
Thyroidectomy, Quality-of-life assessment, entral lymph node dissection (CLND)
Condition
Stage I Papillary Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage III Papillary Thyroid Cancer
Investigators
Rebecca Sippel